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complication of pituitary adenoma, occurring either spontaneously or
precipitated by several factors, among them pituitary function test with
hypothalamic releasing hormones. The mechanism by which releasing
hormones cause pituitary apoplexy is unclear. It has been proposed
that increase in pituitary size and/or alterations in blood flow could be
responsible. The aim of this study was to explore the effects of
intravenous administration of hypothalamic releasing hormones on
pituitary size and hemodynamics in healthy subjects. Gadolinium-
DTPA-enhanced dynamic magnetic resonance imaging (MRI) was
performed in eight healthy volunteers under basal conditions and 20
min after injection of releasing hormones. Mean upslopes of
Gadolinium-DTPA enhancement curves showed good correlation
between basal and stimulated conditions (R = 0.89) and were
significantly steeper after stimulation ( P = 0.017). In contrast, pituitary
height, width and length did not differ significantly between basal and
stimulated conditions. In conclusion, the pituitary does not swell in
healthy subjects in response to stimulation with hypothalamic releasing
hormones, whereas transfer of contrast agent to tissue (blood flow and/
or vessel permeability) is enhanced.
D 2004 Elsevier Inc. All rights reserved.
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Introduction
Pituitary apoplexy is a clinical syndrome characterized by
sudden headache, visual impairment and hormonal dysfunction
due to infarction and/or hemorrhage of a pituitary adenoma
(Cardoso and Peterson, 1984; Randeva et al., 1999). The outcome
is often permanent pituitary insufficiency requiring hormone
replacement therapy (Lamberts et al., 1998; Vance, 1994). Hem-
orrhage is a frequent complication of pituitary adenomas, reported
to occur in up to 10% of adenomas (Fraioli et al., 1990).
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predisposing factors have been described, including pituitary
function tests with hypothalamic releasing hormones (e.g., Drury
et al., 1982; Masago et al., 1995; Riedl et al., 2000; Rotman-
Pikielny et al., 2003).
Since pituitary apoplexy after combined pituitary stimulation
has only been reported in patients with macroadenomas so far, it
has been proposed that the stimulation could cause an increase in
pituitary volume which in turn would lead to infarction due to the
limited space in the rigid walls of the sella (Riedl et al., 2000).
Dynamic contrast-enhanced magnetic resonance imaging
(MRI) using exogenous contrast agents like Gadolinium-DTPA
is a non-invasive tool for studying functional parameters.
Pituitary enhancement patterns have been studied mainly during
and immediately after the first pass of Gadolinium-DTPA
(Bartynski and Lin, 1997; Kanou et al., 2002; Miki et al.,
1990; Tabarin et al., 1998; Yuh et al., 1994). The main
information provided by the contrast agent enhancement curve
is tissue vascularization and perfusion. It is also influenced by
capillary permeability and the volume of interstitial space
(Roberts, 1997). Dynamic Gadolinium-DTPA-enhanced MRI
imaging is widely used in the diagnosis of pituitary adenomas
(Patronas et al., 2003) and is especially useful for detection of
microlesions (Bartynski and Lin, 1997; Patronas et al., 2003).
The normal pituitary gland typically enhances within the first
1–2 min after contrast injection. The enhancement pattern is
consistent with the vasculature architecture of the pituitary with
the posterior lobe enhancing earlier than the anterior lobe
(Sakamoto et al., 1991; Yuh et al., 1994). Delayed enhancement
is found in patients with arteriovenous fistulas in the cavernous
sinus (Shigematsu et al., 2003) and hypopituitarism (Sato et al.,
1998).
The size of the pituitary has been studied in healthy subjects
using MRI and CT measurements and is reported to be 4–7 mm
(height), 10–15 mm (width) and 7–11 mm (length) (see Kato et
al., 2002 and references therein). Different formulas have been
used for calculating pituitary volume of the three parameters, but
none seemed to be superior. Overall, pituitary height has been
proposed as the best single surrogate parameter of pituitary size
(Lurie et al., 1990). Height is maximal in young adults (Kato et al.,
2002; Lurie et al., 1990) and changes with chronic functional
alterations. For example, pituitary height has been shown to
C. Maier et al. / NeuroImage 22 (2004) 347–352348correlate with gestational age during pregnancy (Dinc et al., 1998;
Elster et al., 1991).
Acute changes of the pituitary gland in different activity
states have not been studied in vivo, and it is not known if and
how the pituitary gland is altered upon activation. The goal of
this study on young healthy volunteers was the comparison of
pituitary size and Gadolinium-DTPA enhancement patterns under
basal conditions and after stimulation with hypothalamic-releas-
ing hormones.Methods
Subjects
Ten young (aged 27.3 F 5.6 years), healthy subjects (5 male, 5
female) with a body mass index of 22.7 F 3.6 were included in the
study. Mean blood pressure was 117 F 11/75 F 8. None of the
volunteers had a history of metabolic, gastrointestinal, liver or
kidney disease or did take any medication (including hormonal
contraception). Routine blood chemistry, peripheral blood count
and basal hormone levels were normal. The study was approved by
the local institutional review board, and written informed consent
was obtained from all subjects.
Two of the subjects (one male, one female) had abnormal
findings in the basal MRI scan (pituitary microadenoma and
pituitary hypertrophy) on study day 1 and were excluded from
further analysis.
Study protocol
For each subject, 2 study days were scheduled with intervals of
7 days. On both study days subjects arrived between 7.30 a.m. and
noon after an overnight fast. An intravenous cannula was placed in
an antecubital vein on both study days for Gadolinium-DTPA
injection and collection of blood samples, and for intravenous
injection of releasing hormones on study day 2.
On study day 1, MRI scans were performed under basal
conditions.
On study day 2, MRI scans were performed 20 min after
intravenous injection of hypothalamic releasing hormones—the
time point when the pituitary would be expected to be most active
as judged by peak concentrations of most pituitary hormones. TSH,
ACTH and GH reach their peak values in the circulation after 20–
30 min, Prolactin earlier (10–20 min) and FSH and LH later (30–
45 min) (Cohen et al., 1986).
Stimulation tests
On study day 2, a combined pituitary stimulation test was
performed with intravenous injection of hypothalamic releasing
hormones (corticotropin-releasing hormone, CRH, 100 Ag; thy-
rotropin-releasing hormone, TRH, 200 Ag; growth hormone-
releasing hormone, GHRH, 100 Ag; gonadotropin-releasing
hormone, GnRH, 100 Ag; CRH and GHRH: Ferring Pharma-
ceuticals, Berlin, Germany, TRH and GnRH: Aventis, Frankfurt,
Germany).
Blood samples for determination of ACTH, cortisol, TSH, GH,
LH, FSH and prolactin were drawn before (basal) and 10 min
(before start of MRI), 45 min (after MRI) and 60 min after
injection of hypothalamic releasing hormones.Hormone assays
Hormone levels were determined with commercially avail-
able assays and analyzed on automated immunoassay-analyzers.
LH, FSH, TSH and prolactin were assayed with an Elecsys
2010R (Roche-Diagnostica, Germany), cortisol and GH with
Auto-DELFIAR (Wallc Oy, Finland) and ACTH with an
AdvantageR-System. Day to day imprecision of analyses was
determined by Lyphocheck three level control material (Bio-
Rad, USA), except for ACTH, for which Nichols three level
controls (Nichols Institute Diagnostics, USA) were used. The
coefficients of variation were 4–5% (LH), 2–3% (FSH), 4%
(prolactin), 3–4% (TSH), 3% (GH), 3–5% (cortisol) and 3–9%
(ACTH).
MRI
MR-examinations of the pituitary were performed on a 1.5
T MR unit (Siemens Vision, Siemens, Erlangen, Germany) with
a gradient strength of 23 mT/m. Using a circularly polarized
head coil three localizer sequences in axial, coronal and sagittal
plane were obtained to provide reproducible imaging planes for
the second intraindividual examination. Based on this localizer
sequences, the pituitary was examined on the coronal plane
pre- and postcontrast and in the sagittal plane postcontrast. The
following sequences were applied: a standard T1-weighted spin
echo (SE) sequence (TR/TE: 450/14 ms) before and after
intravenous administration of a double dose (0.2 mmol/kg body
weight) of gadolinium-DTPA (Magnevist, Schering, Berlin,
Germany). The field of view (FOV) was 173  230 mm,
the matrix size 284  512, the slice thickness was 2 mm and
2 acquisitions were collected. Immediately after i.v. administra-
tion of gadolinium-DTPA, a dynamic contrast study was
performed using a standard T1-weighted 2D Gradient-echo
(GRE) sequence (TR/TE/Flip angle: 30/4 ms/30j). Three cor-
onal slices best covering the pituitary were selected from the
native study and the GE sequence was repeated every 20 s
over a total examination time of 3 min. From these data, a
time vs. signal intensity curve was constructed using the scanner
software.
Matching of MRI scans and pituitary size measures
For the second MR examination in each volunteer the
selection of the same coronal and sagittal slices was performed
by three localizer sequences and anatomical landmarks. Based
on these images, maximal height and width (from coronal
planes) and length (from sagittal planes) of the pituitary were
measured using a workstation (Magic View Siemens). Measur-
ing was performed by a single radiologist (S.T.) blinded to the
study days of the images. An example for midlevel slices used
for measurements is given in Fig. 1.
Gadolinium-DTPA enhancement curves
Each time vs. signal intensity curve generated by the scanner
software was converted into the related enhancement curve accord-
ing to the equation
yðtÞ ¼ ðSt  S0Þ=S0  100%
Fig. 1. T1-weighted midlevel slices of pituitary MRI in (a) coronal plane
and (b) sagittal plane. Arrows indicate maximal width and height (a) and
length (b).
 
Fig. 2. Example of individual enhancement curves in basal (x) and
stimulated (.) conditions with peak values ( ymax), peak times (tmax) and
mean upslopes under basal (kbasal) and stimulated (kstim) conditions.
Table 1
Basal and peak hormone concentrations
Hormone Units Basal Peak Time point
of peak
values (min)
ACTH Pg/ml 29.50 F 6.25 51.00 F 11.25 45
Cortisol Ag/dl 14.80 F 4.13 18.65 F 2.20 60
TSH AU/ml 1.35 F 0.34 12.45 F 1.30 45
GH ng/ml 0.40 F1.60 10.60 F 2.50 45
FSH mU/ml 4.25 F 1.08 7.10 F 2.23 60
LH mU/ml 5.45 F 3.00 26.20 F 11.50 45
Prolactin ng/ml 16.75 F 6.38 100.20 F 56.00 10
Hormone Concentrations of eight healthy subjects after combined pituitary
stimulation test with hypothalamic releasing hormones. Data are given as
median F SIR. ACTH, Corticotropin; TSH, Thyrotropin; GH, Growth
hormone; FSH, Follicle-stimulating hormone; LH, Luteinizing hormone.
C. Maier et al. / NeuroImage 22 (2004) 347–352 349where y(t) is enhancement at time point t, S0 the signal intensity of
the first time point (baseline) and St are signal intensities taken
from subsequent images acquired every 20 s.
Data evaluation
Since in this small sample no normal distribution could be
assumed, data are given as median F semi-interquartile range
(SIR) unless stated otherwise and non-parametric tests were
used for statistical evaluation. Statistical evaluation was per-
formed using a commercially available software package (Stat-
view, Abacus).
For basal and stimulated pituitary height, width and length, and
the product of the three values (as a surrogate parameter for
pituitary volume) linear regression analysis was performed to
determine the accuracy of selection of matching MRI slices.
Basal and stimulated values of pituitary measures and basal and
peak hormone levels were compared using Wilcoxon’s signed rank
test.
For each enhancement curve peak value ( ymax) and peak time
(time to reach the peak, tmax) were determined (Fig. 2). Mean
upslopes k were calculated for all enhancement curves according to
the equation:
K ¼ ymax=tmaxThe obtained basal and stimulated values were compared using
linear regression analysis and Wilcoxon’s signed rank test.
P < 0.05 was considered statistically significant.Results
Stimulation tests
An overview of basal and peak hormone concentrations is
shown in Table 1. In each individual, pituitary hormones rose after
injection of hypothalamic releasing hormones, and differences
between basal and peak values were significant for all hormones
(not shown).
Pituitary size
Mean values for pituitary height, length and width, and the
product of the three parameters (as a surrogate for pituitary
volume) are given in Table 2. Pituitary height was <0.9 cm for
all subjects in both basal and stimulated conditions.
Table 2
Pituitary measures
Parameter Basal Stimulated NR z/#/ P (diff) R2
Height 6.30 6.55 5/2/1 0.11 0.965
Width 13.75 13.93 4/3/1 0.20 0.943
Length 10.29 9.99 3/4/1 0.67 0.604
Product 931 939 6/2/0 0.40 0.941
Mean pituitary measures (in mm) and their product (in mm3, as a surrogate
parameter for volume) of matched MRI scans for eight healthy subjects at
baseline and 20 min after stimulation with hypothalamic releasing
hormones. The number of measures increasing (z), decreasing (#) or
remaining the same () after stimulation are given for each parameter.








Fig. 4. Linear regression model of mean upslopes under basal (kbasal) and
stimulated (kstim) conditions in eight healthy volunteers.
C. Maier et al. / NeuroImage 22 (2004) 347–352350None of the measured parameters was significantly different in
the stimulated vs. basal pituitary, nor was the product of the three
parameters. Changes in measures were inconsistent throughout the
subjects. On the other hand, linear regression analysis revealed R2
values > 0.9 for three of the four parameters reflecting excellent
goodness of fit (i.e., matching of MRI sections).
An overview of the changes in measures and results of
statistical analysis are given in Table 2 (although non-parametric
statistical evaluation is used, data are presented as means for the
sake of comparability).
Individual changes in pituitary size parameters are presented in
Figs. 3a–d.Fig. 3. Differences between pituitary size (a–d) and enhancement (e–g) values in
and after stimulation (2). a, width; b, height; c, length; d, volume (width  heigGadolinium-DTPA enhancement
An example for individual basal and stimulated Gadolinium-
DTPA enhancement curves is given in Fig. 2.
Peak values were 124 F 43 and 130 F 71, respectively (R2 =
0.852, P = 0.001). They were reached after 47.5 F 15 (basal) andeight individual subjects (black) and means (red) under basal conditions (1)
ht  length); e, peak time tmax; f, peak value ymax; g upslope k.
C. Maier et al. / NeuroImage 22 (2004) 347–352 35137.5 F 10 s (stimulated), respectively (R2 = 0.223, P = 0.24). P
values for the differences were not significant for both parameters.
Mean upslopes k were significantly steeper in stimulated than in
basal conditions (3.51 F 1.66 vs. 2.63 F 1.24, P = 0.017). The
individual upslopes showed large variations, but correlation be-
tween kbasal and kstim was high with the resulting equation kstim =
0.87  kbasal + 1.36 (R = 0.89, P = 0.003, Fig. 4).
Individual changes of the three parameters are given in
Figs. 3e–g.Discussion
Two out of 10 young, apparently healthy adults turned out to
have abnormal results on pituitary MRI scan and had to be
excluded from the study. This finding in itself is remarkable and
confirms the high frequency of pituitary pathologies in the general
population (Burrow et al., 1981; Hall et al., 1994).
It has been hypothesized that swelling of the pituitary gland
triggers pituitary apoplexy after combined stimulation test with
hypothalamic releasing hormones. Surprisingly, hypothalamic-re-
leasing hormones did not lead to a statistically significant increase
of pituitary size in the eight young healthy individuals in this study
(Figs. 3a–d). Pituitary height, which has been proposed as the best
single surrogate parameter for pituitary volume (Lurie et al., 1990),
did increase in five of the eight subjects studied and decreased in
two. Mean values differed by only 0.25 mm; certainly not enough
to explain the precipitation of apoplexy by stimulation with
hypothalamic hormones. We also used pituitary length and width
and the product of the three parameters as measures of pituitary
size with similar results. Observed changes were only small and
inconsistent, although the matching procedure was accurate and the
reproducibility of MRI scans was high, as shown by the high R2
(goodness-of-fit) values in linear regression analysis (Table 2). The
only parameter that gave an unsatisfying R2 value was pituitary
length, which was taken from sagittal images, whereas the other
two parameters were taken from coronal images. All values were in
the range reported (Kato et al., 2002 and references therein).
In contrast, Gadolinium-DTPA enhancement in the pituitary
was altered significantly after injection of hypothalamic releasing
hormones. In particular, mean upslopes of the enhancement curves
were significantly steeper in stimulated than in unstimulated
pituitary glands (Fig. 3g); thus, transfer of contrast agent to
pituitary tissue is higher indicating increased blood flow and/or
vessel permeability after stimulation with hypothalamic releasing
hormones.
While no major hemodynamic effects of GHRH or GnRH have
been reported TRH (Kondoh et al., 1989) and CRH (Grunt et al.,
1993; Gutkowska et al., 2000) influence the systemic circulation. It
has been shown that the endothelium-derived relexant factor nitric
oxide (NO) is involved in the vasodilatory effects of CRH
(Gutkowska et al., 2000) and that NO is involved in hypothalamic
(Prevot, 2002) and pituitary hormone release and blood flow
(Duvilanski et al., 1995). The results reported here are the first
indication of increased blood flow in pituitary portal vessels
induced by hypothalamic releasing hormones.
Upslopes of Gadolinium-DTPA enhancement curves have been
used successfully to characterize myocardial perfusion in rest and
after adenosine challenge (Nagel et al., 2003; Panting et al., 2002).
Although they cannot provide absolute values of blood flow mean
upslopes are linearly related to perfusion data derived frommicrosphere measurements (Klocke et al., 2001). In our small
sample, individual upslopes of pituitary perfusion varied consid-
erably (Fig. 3g) but the correlation of basal and stimulated upslopes
was high (Fig. 4) and mean upslopes differed significantly (P =
0.017). The absolute values (peak times and peak values) were less
conclusive (Figs. 3e, f). It is possible that true peak times and
values were missed despite the high temporal resolution of 20 s,
which is in the range of most published dynamic MRI studies of
the pituitary. In this study, a standard T1-weighted 2D gradient-
echo sequence has been used to acquire the enhancement curve.
The high temporal resolution was achieved by selecting three
coronal slices covering the pituitary gland from a native series.
This approach would be practicable for routine clinical use.
Adenomas are thought to receive additional arterial blood
supply (Yuh et al., 1994) which would certainly alter hemodynam-
ics. Pituitary adenomas have shown maximum enhancement earlier
(Miki et al., 1990; Sakamoto et al., 1991) and later (Bonneville et
al., 1993; Finelli and Kaufman, 1993) than the normal pituitary
tissue. In a recent dynamic MRI study (Kanou et al., 2002), the
majority of pituitary adenomas reached peak enhancement earlier
than or simultaneously with the normal pituitary glands, whereas
microadenomas tended to have later enhancement patterns. The
clinical significance of our study cannot not be tested in patients
with pituitary macroadenomas due to their increased risk of
pituitary apoplexy. However, it would be of interest to determine
whether patients with microadenomas would react similarly to the
administration of hypothalamic releasing hormones. This would
challenge the hypothesis that changes in size are the underlying
pathomechanism of pituitary apoplexy following pituitary stimu-
lation tests.
In summary, different activity states of the pituitary gland
were studied for the first time by contrast-enhanced dynamic
MRI with high reproducibility. It is shown that pituitary glands
of healthy subjects do not increase in size in response to
intravenous administration of hypothalamic releasing hormones,
whereas pituitary blood flow and/or vessel permeability is
increased upon stimulation.Uncited reference
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